Working together to reduce the global burden of kidney cancer

Kidney cancer is a global issue. Every year, 431,000 people worldwide will be diagnosed with kidney cancer.

Click here for shareable information, graphics and materials about kidney cancer for patient organisations worldwide.

Summary of Kidney Cancer Take-Home Messages from ASCO GU 2021

As a result of the COVID-19 pandemic, this year’s American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium was held virtually from 11-13 February 2021. The virtual presentations are available to view on the ASCO website. The International Kidney Cancer Coalition (IKCC) attended the virtual scientific programme to keep abreast of the latest advances in the care and treatment of people with kidney cancer.

Read more

2021 World Kidney Cancer Day 

‘We need to talk about how we’re feeling’ is the theme for World Kidney Cancer Day 2021. Save the date on 17 June 2021 and join patients, families, friends, carers, health professionals, researchers and local kidney cancer organisations from around the world to raise awareness and reduce the global burden of kidney cancer.

Read more

COVID-19 Cancer-Related Resources

The COVID-19 global pandemic is affecting people around the world and is of great concern to many cancer patients. In addition to information about the virus and how to protect ourselves, kidney cancer patients need information about cancer treatment, follow-up care and other cancer-specific details about managing our health during the pandemic.

Read more

Updates from IKCC

7 hours ago
Excited to share our work on using plasma KIM-1 levels to predict recurrence after kidney cancer surgery. Huge thanks to collaborators including mentor Dr. Rupal Bhatt and @eaonc @Robert_Uzzo @VenkataSabbise1 and many others not on Twitter!
2 days ago
New telemedicine technology may feel intimidating – but it doesn’t have to be. Consider these tips for virtual visits.
3 days ago
Great to see a phase I/Ib study in heavily pretreated metastatic #kidneycancer patients;pegilodecakin, pegylated recombinant human IL-10, as monotherapy or in combination with either pazopanib or pembrolizumab or nivolumab . via @practiceupdate
5 days ago
The #kidneycancer community has been waiting for potential #adujvant treatment for #intermediate / #highrisk patients: Interims analysis: KEYNOTE-564 trial evaluating pembrolizumab met its primary endpoint of disease-free survival. Can't wait for the data!

Did you know?

Kidney cancer is often found by accident.

Kidney cancer is the 12th most prevalent cancer worldwide.

About 59 per cent of kidney cancer cases occur in more developed countries.

Our Global Network

IKCC welcomes every organisation that has an interest in kidney cancer and who pledges to conform to our Code of Conduct. We extend an open invitation to become part of this international network.

Explore Our Global Network

Join our mailing list

In the newsletter we highlight news about kidney cancer diagnosis and treatment, and other relevant discussions.

Sign up